Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.

Arun A AzadAndrew J ArmstrongAntonio AlcarazRussell Z SzmulewitzDaniel P PetrylakJeffrey HolzbeierleinArnauld VillersBoris AlekseevTaro IguchiNeal D ShoreFrancisco Gomez-VeigaBrad RosbrookHo-Jin LeeGabriel P HaasArnulf Stenzl

Published in: Prostate cancer and prostatic diseases (2021)

Enzalutamide plus ADT demonstrated clinical benefit across all patients with mHSPC, irrespective of prior local and systemic treatment, disease volume, and risk.

Keyphrases

prostate cancer
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
stem cells
bone marrow
smoking cessation
breast cancer risk